Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samir H Barghout

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Anti-Cancer Agents in Medicinal Chemistry|April 11, 2020
Targeted Protein Degradation: An Emerging Therapeutic Strategy in CancerSamir H Barghout
Anti-Cancer Agents in Medicinal Chemistry|April 14, 2022
New Frontiers in the Discovery and Development of PROTACsSamir H Barghout
The Journal of Pharmacology and Experimental Therapeutics|January 1, 2026
Emerging pharmacology of targeted protein degradersSamir H Barghout, Mohamed A Eldeeb
Oncotarget|October 23, 2018
The ubiquitin-activating enzyme, UBA1, as a novel therapeutic target for AMLSamir H Barghout, Aaron D Schimmer
Pharmacological Reviews|November 12, 2020
E1 Enzymes as Therapeutic Targets in CancerSamir H Barghout, Aaron D Schimmer
Biochimica Et Biophysica Acta. Gene Regulatory Mechanisms|June 26, 2022
Chemical biology and pharmacology of histone lysine methylation inhibitorsSamir H Barghout, Raquel Arminda Carvalho Machado, Dalia Barsyte-Lovejoy
Biochemical and Biophysical Research Communications|November 3, 2015
Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cellsSamir H Barghout, Nubia Zepeda, Zhihua Xu, et al.
Methods in Molecular Biology (Clifton, N.J.)|August 9, 2023
HiBiT Cellular Thermal Shift Assay (HiBiT CETSA)Sarath Ramachandran, Magdalena Szewczyk, Samir H Barghout, et al.
ACS Pharmacology & Translational Science|November 21, 2022
Combined Targeting of the Glutathione and Thioredoxin Antioxidant Systems in Pancreatic CancerFrancesco Fazzari, Sue Chow, May Cheung, et al.
Gynecologic Oncology|July 19, 2015
RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cellsSamir H Barghout, Nubia Zepeda, Krista Vincent, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Anti-Cancer Agents in Medicinal Chemistry|April 11, 2020
Targeted Protein Degradation: An Emerging Therapeutic Strategy in CancerSamir H Barghout
Anti-Cancer Agents in Medicinal Chemistry|April 14, 2022
New Frontiers in the Discovery and Development of PROTACsSamir H Barghout
The Journal of Pharmacology and Experimental Therapeutics|January 1, 2026
Emerging pharmacology of targeted protein degradersSamir H Barghout, Mohamed A Eldeeb
Oncotarget|October 23, 2018
The ubiquitin-activating enzyme, UBA1, as a novel therapeutic target for AMLSamir H Barghout, Aaron D Schimmer
Pharmacological Reviews|November 12, 2020
E1 Enzymes as Therapeutic Targets in CancerSamir H Barghout, Aaron D Schimmer
Biochimica Et Biophysica Acta. Gene Regulatory Mechanisms|June 26, 2022
Chemical biology and pharmacology of histone lysine methylation inhibitorsSamir H Barghout, Raquel Arminda Carvalho Machado, Dalia Barsyte-Lovejoy
Biochemical and Biophysical Research Communications|November 3, 2015
Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cellsSamir H Barghout, Nubia Zepeda, Zhihua Xu, et al.
Methods in Molecular Biology (Clifton, N.J.)|August 9, 2023
HiBiT Cellular Thermal Shift Assay (HiBiT CETSA)Sarath Ramachandran, Magdalena Szewczyk, Samir H Barghout, et al.
ACS Pharmacology & Translational Science|November 21, 2022
Combined Targeting of the Glutathione and Thioredoxin Antioxidant Systems in Pancreatic CancerFrancesco Fazzari, Sue Chow, May Cheung, et al.
Gynecologic Oncology|July 19, 2015
RUNX3 contributes to carboplatin resistance in epithelial ovarian cancer cellsSamir H Barghout, Nubia Zepeda, Krista Vincent, et al.
Pageof 3